by October Gallery
LONDON (Reuters) – A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare…
GENEVA (Reuters) – A doctor has become the first probable Ebola case in one of the eastern Democratic Republic of Congo’s most violence-ridden and inaccessible zones, a scenario “we have…
SHANGHAI (Reuters) – China said on Saturday it has sacked six senior officials at its food and drug regulator after a safety scandal at vaccine maker Changsheng Biotechnology Co Ltd…
LONDON (Reuters) – A long-acting injection developed by GlaxoSmithKline (GSK.L) and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects…
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.…
HONG KONG (Reuters) – China Tower Corp Ltd’s (0788.HK) shares closed flat on their debut in Hong Kong on Wednesday, with escalating Sino-U.S. trade tensions dragging on investor sentiment toward…
(Reuters) – Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys shares slid nearly 9 percent…
LONDON (Reuters) – GlaxoSmithKline’s new research boss aims to turbo-charge the British group’s drug discovery engine with a $300 million bet on genetics by buying a stake in the Silicon…
SHANGHAI (Reuters) – A vaccine scandal in China, which has prompted angry reactions from leaders and citizens fed up with safety scares in the country, is sending ripples across the…
(Reuters) – Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after…